Singapore Markets closed

NeuroSense Therapeutics Ltd. (NRSN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.7100+0.0500 (+3.01%)
As of 01:05PM EDT. Market open.

NeuroSense Therapeutics Ltd.

Building B
11 HaMenofim Street
Herzliya 4672562
972 9 799 6183

Full-time employees11

Key executives

NameTitlePayExercisedYear born
Mr. Alon Ben-NoonCo-Founder, CEO & DirectorN/AN/A1979
Mr. Or EisenbergChief Financial OfficerN/AN/A1981
Ms. Hagit BinderVP of OperationsN/AN/A1978
Ms. Yael BarakHead of QA & ComplianceN/AN/A1970
Ms. Nedira Salzman-FrenkelGlobal Head of Bus. Devel.N/AN/A1988
Dr. Shiran Zimri Ph.D.Head of Scientific ProgramN/AN/A1985
Dr. Ferenc Tracik M.D.Chief Medical OfficerN/AN/A1965
Dr. Niva Russek-Blum Ph.D.Global Head of Discovery & IP GeneratorN/AN/A1975
Dr. Sharon Cohen Vered Ph.D.Global Head of CMCN/AN/A1966
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Corporate governance

NeuroSense Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.